Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**N040** is an investigational Thai/Lanna multi-herb medicinal formula selected from the MANOSROI III traditional-recipe database for potential treatment of cervical cancer. It is a chemically heterogeneous botanical extract rather than a defined single active substance. Preclinical work reported potent antiproliferative activity against HeLa cervical-cancer cells and tumor-growth inhibition in a HeLa xenograft model; *Caesalpinia sappan* was the most active individual plant tested, and brazilin isolated from that plant showed in-vitro activity, but brazilin is not established as the sole active constituent of N040. A published phase 1b study administered oral N040 extract capsules to patients with advanced cervical cancer who were not eligible for standard treatment. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/23831080/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N040.